Opinion
Video
Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections
Author(s):
Key Takeaways
- Rebyota's FDA approval was based on clinical trial data showing significant reduction in CDI recurrence rates compared to placebo.
- The pivotal trial was a randomized, double-blind, placebo-controlled study demonstrating Rebyota's efficacy in recurrent CDI.
The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile infections.
Video content above is prompted by the following:
- What is the key data that led to the FDA approval of Rebyota for recurrent C difficile infection?
- Who are the target patient populations for Rebyota?
Related Videos
Related Content
